Main Industry
Biotechnology
Main Product/Service
Fc-Based Designer Biologics (FBDB™) with unique molecular configurations. The core technology of HanchorBio, Inc. (TW) is the FBDB™ (Fc-Based Designer Biologics) technology platform, which focuses on the research and development of next-generation cancer immunotherapy fusion protein biologics. It primarily utilizes the antibody Fc region as a scaffold and employs protein engineering technology to construct various engineered anti-cancer macromolecules onto this scaffold. By combining these methods with AI-assisted drug design capabilities, the platform is dedicated to solving the challenges in cancer immunotherapy.
The content above was translated by Ai
Founded Year
2020
Unified Business No.
83156464
Status
Active
Number of Employees
70
Total Paid-in
Capital
170,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2025)、Innovation Board(2026)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
HanchorBio, Inc. (TW) was established at the end of 2020, focusing on the development of novel drugs for cancer and autoimmune diseases. Since its inception, it has pioneered precise tumor treatment models using its proprietary FBDB™ technology platform. Through unique drug design and clinical strategies, it drives cancer treatment toward a more effective and safer new era.
Recipient of multiple awards — highly recognized. 2024 Merck Biotech Grant Program Grand Prize; 2024 The 21st National Innovation Award — Enterprise Innovation Award; 2025 IMAPAC Taiwan Biopharma Excellence Awards; 2025 Outstanding Biotech Industry Award — Outstanding Start-up Award; 2025 National Innovation Refinement Award.
HanchorBio, Inc. (TW) was founded by Dr. Scott Liu, the former co-founder of Henlius, a Hong Kong-listed company, and was listed on the Emerging Stock Board in 2025 (7827.TWO). Focusing on the development of innovative fusion protein biologics for cancer and autoimmune diseases, the company is committed to becoming a global leader in innovative tumor therapies. It pioneers the flexible combination of different targets using its proprietary FBDB™ technology platform to create precise tumor treatment models, driving cancer treatment toward a more effective and safer new era through unique drug design and clinical strategies.
Leveraging its industry-leading fusion protein design capabilities and rapid drug development processes, HanchorBio, Inc. (TW) advances its R&D pipeline across diverse tumor indications to unleash the innovative potential of the biopharmaceutical industry.
As of 2025, HanchorBio, Inc. (TW) has utilized the FBDB™ platform to advance more than 8 R&D pipelines, covering multiple fields such as immune checkpoints, tumor microenvironment regulation, and tumor-specific antigens; in terms of patent portfolio, it has accumulated more than 100 patent applications globally, demonstrating strong R&D and intellectual property capabilities. The company has offices in Taipei, Shanghai, and San Francisco, with its R&D center located in Taipei.
Recipient of multiple awards — highly recognized. 2024 Merck Biotech Grant Program Grand Prize; 2024 The 21st National Innovation Award — Enterprise Innovation Award; 2025 IMAPAC Taiwan Biopharma Excellence Awards; 2025 Outstanding Biotech Industry Award — Outstanding Start-up Award; 2025 National Innovation Refinement Award.
HanchorBio, Inc. (TW) was founded by Dr. Scott Liu, the former co-founder of Henlius, a Hong Kong-listed company, and was listed on the Emerging Stock Board in 2025 (7827.TWO). Focusing on the development of innovative fusion protein biologics for cancer and autoimmune diseases, the company is committed to becoming a global leader in innovative tumor therapies. It pioneers the flexible combination of different targets using its proprietary FBDB™ technology platform to create precise tumor treatment models, driving cancer treatment toward a more effective and safer new era through unique drug design and clinical strategies.
Leveraging its industry-leading fusion protein design capabilities and rapid drug development processes, HanchorBio, Inc. (TW) advances its R&D pipeline across diverse tumor indications to unleash the innovative potential of the biopharmaceutical industry.
As of 2025, HanchorBio, Inc. (TW) has utilized the FBDB™ platform to advance more than 8 R&D pipelines, covering multiple fields such as immune checkpoints, tumor microenvironment regulation, and tumor-specific antigens; in terms of patent portfolio, it has accumulated more than 100 patent applications globally, demonstrating strong R&D and intellectual property capabilities. The company has offices in Taipei, Shanghai, and San Francisco, with its R&D center located in Taipei.
The content above was translated by Ai
